Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-12 | Kathleen Goetz: Ms. Goetz was Vice President Head of Sales at Novartis Pharmaceuticals until 2019. Ms. Goetz serves on the Audit Committee and Valuation Committee of each Fund. Kathleen L. Goetz was appointed as a Trustee effective December 9, 2021. No compensation data was provided for Kathleen L. Goetz. |
| 2023-04-11 | Ms. Goetz brings to the Fund over 30 years of healthcare business and leadership experience. She serves on the Audit Committee and Valuation Committee of the Fund. For the fiscal year ended September 30, 2022, the Independent Trustees as a group received $2,098 from HQH, $2,037 from THQ and $1,140 from THW for reimbursed expenses. The following table sets forth information regarding compensation of the Trustees and Executive Officer by each Fund for the fiscal year ended September 30, 2022... Kathleen L. Goetz $95,917 total compensation. |
| 2023-07-10 | Kathleen L. Goetz serves on the Audit Committee and Valuation Committee of the Fund. For the fiscal year ended September 30, 2022, she received $23,979 from each Fund, totaling $95,917. |
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-12 | Ms. Goetz was Vice President Head of Sales at Novartis Pharmaceuticals... Ms. Goetz holds a Business Finance degree from Iowa State University. |
| 2023-04-11 | Ms. Goetz brings to the Fund over 30 years of healthcare business and leadership experience. She brings extensive knowledge of healthcare markets, with leadership experience across product development, operational effectiveness, organizational governance and design, and marketing and sales strategy. |
Data sourced from SEC filings. Last updated: 2025-12-07